Adagio Therapeutics

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adagio recently announced that lab data has proven the effectiveness of its antibody treatment. ADGI stock is up more than 40% on the news.

Why Is Adagio Therapeutics (ADGI) Stock Up Today?

Adagio Therapeutics Inc's (NASDAQ: ADGI) Phase 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19 have met its primary endpoints. Following the emergence of the omicron variant, a pre-specified exploratory.

Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment

Investors are reacting to better than expected clinical trial results for its COVID-19 treatment candidate.

Why Adagio Therapeutics Stock Is Soaring Today.

Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment.

Why Adagio Therapeutics Stock Is Soaring Today

Adagio Therapeutics says it will seek an emergency use authorization for its Covid-19 antibody, known as ADG20, in the second quarter.

Adagio Stock Spikes on New Data, but Its Omicron Problems Remain

Direct Digital Holdings

Vyant Bio

Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 30th, 2022

Shares of Adagio Therapeutics Inc. ADGI, +1.05% soared 53.2% in premarket trading on Wednesday after the company said its experimental COVID-19 monoclonal antibody worked as a treatment and for pre-and-post-exposure prophylaxis in a Phase 2/3 clinical trial. Adagio said it plans to seek authorization from the Food and Drug Administration in the second quarter of this year.

Adagio's stock jumps as company says it will seek authorization for COVID-19 antibody treatment

Vir Biotechnology

Markets looked to take a breather after a huge surge in recent weeks.

These 2 Nasdaq Biotech Stocks Are Soaring Wednesday Morning

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in  pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authoriza

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time on May 26, 2022. Additional information regarding the Company's 2022 Annual Meeting of Stockholders will be disclosed in the Company's Proxy Statement to be filed with the Securities and Exchange Commission.

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the company's Board of Directors has appointed David Hering interim chief executive officer, effective immediately. Mr. Hering, who will also remain the company's chief operating officer, succeeds Tillman Gerngross, Ph.D., who has resigned as CEO and director of Adagio.

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

Adagio Therapeutics Inc (NASDAQ: ADGI) has outlined strategic initiatives for its ADG20 program and research efforts to address SARS-CoV-2 and other coronaviruses.  ADG20 is an investigational monoclonal antibody (mAb) being developed to prevent and treat COVID-19.

Adagio Lays Out Development Plans For COVID-19-Focused ADG20 Program

Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a Chief Executive Officer succession plan. Current Adagio CEO Tillman Gerngross, Ph.D. has communicated to the Chairperson of the Board of Directors of Adagio that he agreed in principle to resign from his position as CEO. Upon Dr. Gerngross's departure from the Company, the Board intends to appoint Mr. David Hering, M.B.A., who has served as the Company's Chief Operating Officer, as Interim Chief Executive Officer of the Company. Dr. Gerngross also agreed to transfer the duties of the Chief Executive Officer to Mr. Hering.

Adagio Therapeutics Announces CEO Succession Plan

Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron.

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Allakos Inc

Alnylam Pharmaceuticals

argenx

BridgeBio Pharma Inc

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19.

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

BioNTech SE

Novavax

Pacific Biosciences of California

Vertex Pharmaceuticals

Could these biotech stocks be poised for gains in 2022?

5 Top Biotech Stocks To Watch In January 2022

The stock price of Adagio Therapeutics Inc (NASDAQ: ADGI) increased by over 16% during intraday trading today. This is why it happened.

Adagio Therapeutics Stock (ADGI): Why The Price Went Up Today

Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET.

Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

The prospects for Adagio's experimental COVID antibody therapy appear to be bleak.

Should Adagio Say Goodbye to Its COVID-19 Hopes?

Another analyst gets notably less bullish on the company's prospects.

Why Adagio Therapeutics Stock Dived by 13% Today

The stock price of Adagio Therapeutics Inc (NASDAQ: ADGI) increased by over 120% today. This is why it happened.

Adagio Therapeutics Stock (ADGI): Why The Price Surged Over 120% Today

Shares of ADGI stock have more than doubled today. With no direct news, investors are curious to know what is driving the price momentum.

News for Adagio Therapeutics Stock (ADGI)